In a meta-analysis including 2703 patients with non-small cell lung cancer (NSCLC), survivin expression was identified as a factor indicative of poorer prognosis in advanced stages of NSCLC (stages III-IV) rather than early stages (I-II) [182]. The gene discussed is BIRC5; the disease is non-small cell lung carcinoma.